Range Impact (RNGE) 10-Q 17 Feb 15 2015 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 31, 2014	Feb. 13, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stevia First Corp.
Entity Central Index Key	1438943
Current Fiscal Year End Date	-28
Entity Filer Category	Smaller Reporting Company
Trading Symbol	STVF
Entity Common Stock, Shares Outstanding		72,928,915
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Dec. 31, 2014	Mar. 31, 2014
Current Assets
Cash	$1,051,477	$1,403,403
Accounts receivable, net	39,723
Inventory	34,770
Prepaid expenses	9,464	10,637
Advance payment on related party lease		10,413
Total Assets	1,135,434	1,424,453
Current Liabilities
Accounts payable and accrued liabilities	137,329	79,915
Accounts payable - Related Party	1,000	16,100
Derivative liability	1,488,535	1,438,814
Total liabilities	1,626,864	1,534,829
Stockholders' Equity (Deficit)
Common stock, par value $0.001 per share; 525,000,000 shares authorized; 72,928,915 and 66,832,523 shares issued and outstanding	72,929	66,833
Unvested, issued common stock		-149,714
Additional paid-in-capital	10,968,129	8,299,366
Accumulated deficit	-11,532,488	-8,326,861
Total stockholders' deficit	-491,430	-110,376
Total liabilities and stockholders' deficit	$1,135,434	$1,424,453

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Statement Of Financial Position
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	525,000,000	525,000,000
Common stock, shares issued	72,928,915	66,832,523
Common stock, shares outstanding	72,928,915	66,832,523

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Income Statement
Revenue	$59,641		$187,777
Cost of goods sold	20,234		54,215
Gross profit	39,407		133,562
Operating expenses:
General and administrative	655,950	796,017	2,155,676	2,120,541
Rent and other related party costs	9,900	42,150	40,117	115,250
Research and development	365,850	219,436	819,493	545,821
Total operating expenses	1,031,700	1,057,603	3,015,286	2,781,612
Loss from operations	-992,293	-1,057,603	-2,881,724	-2,781,612
Other income (expenses)
Cost to induce exercise of warrants		-173,824	-961,767	-173,824
Interest expense	-102	-88,842	-4,814	-323,929
Change in fair value of derivative liability	-149,686	275,232	642,678	553,343
Total other income (expense)	-149,788	12,566	-323,903	55,590
Net loss	($1,142,081)	($1,045,037)	($3,205,627)	($2,726,022)
Loss per share - basic and diluted	($0.02)	($0.02)	($0.05)	($0.05)
Weighted average number of common shares outstanding- basic and diluted	72,573,650	62,513,640	69,408,309	58,859,776

CONDENSED_STATEMENTS_OF_STOCKH

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]	Unvested Issued Common Stock [Member]	Total
Balance, amount at Mar. 31, 2014	$66,833	$8,299,366	($8,326,861)	($149,714)	($110,376)
Balance, shares at Mar. 31, 2014	66,832,523
Reclassification of unvested issued common stock to paid-in capital		-149,714		149,714
Common stock issued upon exercise of stock options, value	50	4,950			5,000
Common stock issued upon exercise of stock options, shares	50,000				50,000
Common stock issued to employees, value	1,500	221,103			222,603
Common stock issued to employees, shares	1,500,000
Common stock issued for services, value	870	323,230			324,100
Common stock issued for services, shares	869,920
Fair value of vested stock options		177,271			177,271
Fair value of vested warrants granted to employees		355,742			355,742
Common stock issued upon exercise of warrants, value	3,676	1,466,813			1,470,489
Common stock issued upon exercise of warrants, shares	3,676,472
Extinguishment of derivative liability		269,368			269,368
Net loss			-3,205,627		-3,205,627
Balance, amount at Dec. 31, 2014	72,929	10,968,129	-11,532,488		-491,430
Balance, shares at Dec. 31, 2014	72,928,915
Balance, amount at Nov. 30, 2014
Reclassification of unvested issued common stock to paid-in capital				149,714
Common stock issued for services, value	100,000
Common stock issued for services, shares	277,009
Balance, amount at Dec. 31, 2014	$72,929
Balance, shares at Dec. 31, 2014	72,928,915

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net loss	($3,205,627)	($2,726,022)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of vested stock options	177,271	868,497
Fair value of vested common stock issued to employees	222,603	28,029
Change in fair value of derivative liability	-642,678	-553,343
Fair value of common stock issued for services	324,100
Fair value of vested warrants granted to employees	355,742
Cost to induce exercise of warrants	961,767	173,824
Amortization of debt discount		295,804
Changes in operating assets and liabilities:
Accounts receivable	-228
Inventory	-34,770
Prepaid expenses	1,173	-233
Advance payment on related party lease	10,413	93,753
Accounts payable and accrued liabilities	7,414	194,247
Accounts payable - related party	-15,100	2,270
Accrued interest		28,125
Net cash used in operating activities	-1,837,920	-1,595,049
Investing activities
Acquisition of cash upon acquisition	10,505
Net cash provided by investing activities	10,505
Financing activities
Proceeds from exercise of warrants, net	1,470,489	1,824,505
Proceeds from exercise of options	5,000	76,000
Proceeds from sale of common stock, net		1,133,250
Net cash provided by financing activities	1,475,489	3,033,755
Net increase (decrease) in cash	-351,926	1,438,706
Cash and cash equivalent - beginning of period	1,403,403	392,483
Cash and cash equivalent - end of period	1,051,477	1,831,189
Cash paid during the period for:
Interest	4,814
Non-cash activities:
Issuance of common stock upon conversion of notes payable and accrued interest		367,500
Fair value of warrants issued with common stock recorded as derivative liability		1,249,025
Acquisition of accounts receivable upon acquisition	39,495
Extinguishment of derivative liability	269,368	185,907
Cancellation of accounts payable applied to option exercise price		$140,000

BUSINESS_AND_BASIS_OF_OPERATIO

BUSINESS AND BASIS OF OPERATIONS	9 Months Ended
	Dec. 31, 2014
BUSINESS AND BASIS OF OPERATIONS [Abstract]
BUSINESS AND BASIS OF OPERATIONS	STEVIA FIRST CORP.
	NOTES TO CONDENSED FINANCIAL STATEMENTS
	THREE AND NINE MONTHS ENDED DECEMBER 31, 2014
	(Unaudited)
	1. BUSINESS AND BASIS OF OPERATIONS
	Stevia First Corp. (the “Company”, “we”, “us” or “our”) was incorporated under the laws of the State of Nevada on June 29, 2007. In February 2012, we substantially changed our management team, added other key personnel, and began leasing laboratory and office space and land in California and since then we have been pursuing our new business as an agricultural biotechnology company engaged primarily in developing novel methods and technologies for industrial production of stevia, using such methods and technologies to develop, obtain approval for and commercialize one or more stevia extract products, and exploring and commercializing additional research applications for such methods and technologies.
	Going Concern
	These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.  The Company has incurred losses and utilized cash in operations since inception resulting in an accumulated deficit of $11,532,488 as at December 31, 2014, and further losses are anticipated in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2014 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.
	The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the business for the 9 months after December 31, 2014. We will require additional financing to fund our planned long-term operations, including our commitment under our distribution and license agreements with Qualipride International (“Qualipride”) (See Note 9) . These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period.  In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.
	We do not have any firm commitments for future capital.  Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all.  If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations.  If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.
	Basis of Presentation of Unaudited Condensed Financial Information
	The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”) .  Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete audited financial statements.  However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period .  The balance sheet information as of March 31, 2014 was derived from the audited financial statements as of and for the year ended March 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 30, 2014. These financial statements should be read in conjunction with that report.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of shares issued for services, the fair value of options and warrants, and assumptions used in the valuation of our outstanding derivative liabilities.
	Accounts Receivable
	The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding.
	The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At December 31, 2014, the allowance for doubtful accounts and returns and discounts was approximately $3,000.
	Financial Assets and Liabilities Measured at Fair Value
	The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the condensed balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by the Financial Accounting Standards Board (“FASB”) defines the following levels directly related to the amount of objectivity associated with the inputs to fair valuation of these financial assets:
	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.
	Level 3	Unobservable inputs based on the Company’s assumptions.
	The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2014 and March 31, 2014:
	31-Dec-14
			Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability		$	-	$	1,488,535	$	-	$	1,488,535
	31-Mar-14
			Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability		$	-	$	1,438,814	$	-	$	1,438,814
	The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.
	Derivative Financial Instruments
	The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2014 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	Income Taxes
	The Company follows the asset and liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
	Revenue Recognition
	Revenue is recognized on the sale of a product when the risk of loss transfers to our customers and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and our credit acceptance procedures have been performed. The allowance for returns is regularly reviewed and adjusted by management based on historical trends of returned items. Amounts paid by customers for shipping and handling costs are included in sales.
	Stock-Based Compensation
	The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.
	Basic and Diluted Loss Per Share
	The Company computes loss per share in accordance with FASB ASC 260, “Earnings Per Share” which requires presentation of both basic and diluted earnings or loss per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Diluted loss per share excludes all potential common shares if their effect is anti-dilutive.
	As of December 31, 2014 and 2013, the Company had potentially dilutive instruments outstanding whose shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive. Options to acquire 6,025,000 shares of common stock and warrants to acquire 12,127,129 shares of common stock have been excluded from the calculation at December 31, 2014, as the effect would have been anti-dilutive. Options to acquire 4,975,000 shares of common stock, warrants to acquire 7,721,129 shares of common stock, and 693,773 common shares potentially issuable under convertible note agreements have been excluded from the calculation at December 31, 2013, as the effect would have been anti-dilutive.
	Recent Accounting Pronouncements
	In November 2014, the FASB issued Accounting Standards Update No. 2014-16 (ASU 2014-16), Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity.   The amendments in this ASU do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required.  The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract.  The ASU applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015.  Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2014-16 on the Company's results of operations or financial condition
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (“ASU 2014-15”),  Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.  An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.  ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2014-15 on the Company's results of operations or financial condition.
	On June 10, 2014, the FASB issued Accounting Standards Update No. 2014-10 (“ASU 2014-10”), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.  ASU 2014-10 eliminates the requirement that development stage entities present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 are no longer required for interim and annual reporting periods beginning after December 15, 2015, although early adoption is permitted. The Company adopted the provisions of ASU 2014-10 as of its Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers . ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principles-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on the Company’s ongoing financial reporting.
	In April 2014, the FASB issued Accounting Standards Update No. 2014-08 (“ASU 2014-08”), “Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ” ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations or that have a major effect on the Company's operations and financial results should be presented as discontinued operations. This new accounting guidance is effective for annual periods beginning after December 15, 2014. The Company is currently evaluating the impact of adopting ASU 2014-08 on the Company's results of operations or financial condition.
	Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

ACQUISITION_FROM_RELATED_PARTY

ACQUISITION FROM RELATED PARTY	9 Months Ended
	Dec. 31, 2014
ACQUISITION FROM RELATED PARTY [Abstract]
ACQUISITION FROM RELATED PARTY	3. ACQUISITION FROM RELATED PARTY
	On May 16, 2014, the Company entered into an Asset Purchase Agreement with Percipio Biosciences, Inc. (“Percipio”), a Delaware corporation, to purchase certain assets of Percipio for $50,000. The Company’s Chief Executive Officer, Robert Brooke, owns 20% of Percipio. The acquisition of the assets has been accounted for as a purchase in accordance with ASC Topic 805 Business Combinations and the assets have been included in the Company’s financial statements since May 16, 2014. The purchase price was allocated to current assets based on their fair value as determined by management. At December 31, 2014, $14,800 of the purchase price remains unpaid and is included in accounts payable on the accompanying balance sheet. The Company has determined that the acquisition is not a material acquisition and accordingly, no pro-forma information has been presented.
	In conjunction with the Percipio asset purchase, we entered into written employment agreement with Dr. Fang Lu, majority owner and President of Percipio, under which he now serves as Senior Scientist for the Company. Dr. Lu’s employment agreement commenced on May 17, 2014 and is terminable at any time at the option of Dr. Lu or the Company. Under the employment agreement, Dr. Lu is entitled to an annual salary of $95,000.

DERIVATIVE_LIABILITY

DERIVATIVE LIABILITY	9 Months Ended
	Dec. 31, 2014
DERIVATIVE LIABILITY [Abstract]
DERIVATIVE LIABILITY	4. DERIVATIVE LIABILITY
	In June 2008, the FASB issued authoritative guidance on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock.  Under the authoritative guidance, effective January 1, 2009, instruments which do not have fixed settlement provisions are deemed to be derivative instruments.  The warrants issued to investors and placement agents in relation to the June 2013 securities purchase agreements and the new warrants issued to such investors in September 2014 as part of an early exercise offer (described in Note 7), do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future.  The Company was required to include the reset provisions in order to protect the holders of the warrants from the potential dilution associated with future financings. In accor`dance with the FASB authoritative guidance, the warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.
	As of December 31, 2014, September 10, 2014 (date of modification of the warrants), and March 31, 2014, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:
	Warrants:
		31-Mar-14			Date of Modification			31-Dec-14
	Exercise Price	$	0.34-0.42		$	0.40-0.45		$	0.34 – 0.45
	Stock Price	$	0.41		$	0.42		$	0.37
	Risk-free interest rate		0.07-1.73	%		1.78-2.0	%		0.99-1.65	%
	Expected volatility		92.15	%		84.45	%		81.84	%
	Expected life (in years)		0.5-4.25 years			0.1-5.0 years			2.75-4.75 years
	Expected dividend yield		0			0			0
	Fair Value:	$	1,438,814		$	961,767		$	1,488,535
	The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration dates of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.
	As of March 31, 2014, the Company’s derivative liabilities had a balance of $1,438,814. On September 10, 2014, certain terms of certain of the Company’s warrants were modified in connection with an early exercise offer made to the warrant holders, and the incremental change in their fair values of $21,218 was accounted for as an increase in the fair value of the derivative liabilities as of the date of modification and recorded as a cost to induce exercise of the warrants. Also, as part of the terms of the early exercise offer, the Company issued to such warrant holders new, replacement warrants with an aggregate fair value at their issue date of $940,549, which was accounted for as a derivative liability at the issue date (described in Note 7). All of the warrants subject to the early exercise offer, which were accounted for as derivative liabilities, were exercised in connection with such offer, and as such their corresponding fair value at the exercise date of $269,368 was extinguished from the derivative liabilities balance. For the nine month period ended December 31, 2014, the Company recorded a change in fair value of the derivative liability of $642,678. As of December 31, 2014, the aggregate fair value of the derivative liabilities was $1,488,535.

EQUITY

EQUITY	9 Months Ended
	Dec. 31, 2014
EQUITY [Abstract]
EQUITY	5. EQUITY
	Common stock issued to employees
	During the period ended December 31 2014, the Company issued an aggregate of 1,500,000 shares of its common stock to three new employees of the Company pursuant to their employment agreements (See Notes 3 and 9), 100,000 of which were issued under the Company's stock option and incentive plan (the “2012 Stock Incentive Plan”). Of the 1,500,000 shares of common stock issued, 450,000 shares, valued at $135,000, vested immediately and was recognized as expense during the nine months ended December 31, 2014.  The remaining 1,050,000 shares, valued at $315,000, vest over a period ranging from one year to three years. During the nine months ended December 31, 2014, the Company amortized $222,603, of the fair value of the common stock that vested during the period then ended, and recognized such amounts as stock-based compensation in the Company’s statement of operations during the period then ended.
	The Company reclassified $149,714 from unvested, unissued common stock to additional paid-in capital relating to the unvested portion of these shares as of March 31,2014, to make its presentation of stockholders’ deficit reflect the transaction more appropriately.  There was no net effect on stockholders’ deficit.
	Common stock issued to consultant for services
	In May 2014, the Company issued 224,047 shares of the Company’s common stock to a consultant as payment for services and recorded an expense of $94,100 based on the closing market price of our common stock on the date of the issuance. These shares were issued outside of the 2012 Stock Incentive Plan.
	In August 2014, the Company issued 147,058 shares of the Company’s common stock to a consultant as payment for services and recorded an expense of $50,000 based on the closing market price of our common stock on the date of the issuance. These shares were issued outside of the 2012 Stock Incentive Plan.
	In November and December 2014, the Company issued 142,858 and 277,009 shares, respectively, of the Company’s common stock to a consultant as payment for services and recorded an expense of $50,000 and $100,000, respectively, based on the closing market price of our common stock on the date of the issuance. These shares were issued outside of the 2012 Stock Incentive Plan.
	In December 2014, the Company issued 78,948 shares of common stock under the 2012 Stock Incentive Plan to a consultant under the terms of a consulting agreement and recorded an expense of $30,000 based on the closing market price of our common stock on the date of issuance.

STOCK_OPTIONS

STOCK OPTIONS	9 Months Ended
	Dec. 31, 2014
STOCK OPTIONS [Abstract]
STOCK OPTIONS	6. STOCK OPTIONS
	Pursuant to the terms of the 2012 Stock Incentive Plan, the exercise price for all equity awards issued under the 2012 Stock Incentive Plan is based on the market price per share of the Company’s common stock on the date of grant of the applicable award.
	A summary of the Company’s stock option activity for the nine months ended December 31, 2014 is presented below:
		Shares		Weighted Average Exercise Price
	Balance at March 31, 2014		5,150,000	$	0.26
	Granted		950,000		0.36
	Exercised		-50,000		0.10
	Cancelled		-25,000		0.47
	Balance outstanding at December 31, 2014		6,025,000	$	0.32
	Balance exercisable at December 31,2014		5,054,170	$	0.31
	At December 31, 2014, options to purchase common shares were outstanding as follows:
		Number of options		Weighted Average Exercise Price		Weighted Average Grant-date Stock Price
	Options Outstanding, December 31, 2014		1,300,000	$	0.10	$	1.00
			200,000	$	0.27	$	0.27
			100,000	$	0.31	$	0.31
			750,000	$	0.32	$	0.32
			50,000	$	0.33	$	0.33
			250,000	$	0.34	$	0.34
			500,000	$	0.35	$	0.35
			100,000	$	0.36	$	0.36
			150,000	$	0.38	$	0.38
			1,600,000	$	0.40	$	0.40
			225,000	$	0.42	$	0.42
			100,000	$	0.44	$	0.44
			100,000	$	0.47	$	0.47
			600,000	$	0.51	$	0.51
			6,025,000
	Options Exercisable, December 31, 2014		1,300,000	$	0.10	$	1.00
			166,666	$	0.27	$	0.27
			100,000	$	0.31	$	0.31
			750,000	$	0.32	$	0.32
			400,000	$	0.35	$	0.35
			33,336	$	0.36	$	0.36
			1,600,000	$	0.40	$	0.40
			79,168	$	0.42	$	0.42
			25,000	$	0.44	$	0.44
			600,000	$	0.51	$	0.51
			5,054,170
	During the nine months ended December 31, 2014, the Company granted to employees options to purchase an aggregate of.  700,000 shares of the Company’s common stock that expire ten years from the date of grant and have vesting periods ranging from 0 months to 36 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 81.84 %, (ii) discount rate of 1.62 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $194,800.
	During the nine months ended December 31, 2014, the Company also granted to three consultants options to purchase 250,000 shares of the Company’s common stock that expire between five and ten years from date of grant and have vesting periods ranging from is 0 to 36 months. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 81.84 %, (ii) discount rate of 2.17 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The total fair value of the option grants to the consultants at their grant dates was approximately $59,750.
	During the nine months ended December 31, 2014 and 2013, we expensed total stock-based compensation related to vesting stock options of $177,271 and $868,497, respectively, and the remaining unamortized cost of the outstanding stock options at December 31, 2014 was $224,880. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded.
	The intrinsic values of all outstanding and exercisable stock options at December 31, 2014 were approximately $441,000 and $419,500,  respectively.

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2014
WARRANTS [Abstract]
WARRANTS	7. WARRANTS
	At December 31, 2014, warrants to purchase common shares were outstanding as follows:
		Shares		Weighted Average Exercise Price
	Balance at March 31, 2014		7,727,129	$	0.41
	Granted		8,076,472		0.37
	Exercised		-3,676,472		0.40
	Cancelled		-	$	-
	Balance outstanding and exercisable at December 31, 2014		12,127,129	$	0.39
	Warrants issued to induce exercise
	The purchasers who entered into the Securities Purchase Agreement with the Company on June 25, 2013, were issued warrants to purchase up to 11,029,416 shares of the Company’s common stock. The warrants were issued in three series of 3,676,472 each and had exercise prices of $0.40, $0.42 (as reset) and $ 0.42 (as reset) per share, respectively, are exercisable immediately upon issuance, and have a term of exercise equal to five years,  six months, and nine months, respectively. The Company also issued warrants to purchase up to 294,185 shares of the Company’s common stock to its placement agent in the financing. The placement agent warrants have an exercise price of $ 0.425 per share and a term of five years and are exercisable immediately. During the year ended March 31, 2014, warrants to purchase 3,676,472 shares of common stock were exercised based on a reset exercise price of $0.42 per share.
	On March 26, 2014, we extended the expiration date of the nine-month warrants from March 28, 2014 to September 30, 2014. On September 9, 2014, we offered the purchasers holding the nine-month warrants the right to exercise all of those warrants, for an aggregate of 3,676,472 shares of our common stock, based on the terms of an early exercise offer wherein such warrants became exercisable at a reduced exercise price of $0.40 per share and new warrants would be issued to such investors, so long as the exercise thereof occurred on or before September 10, 2014. All purchasers acted on the early exercise offer and we issued 3,676,472 shares of our common stock for gross proceeds to us of $1,470,589. We determined that the modification of the exercise price of the warrants from $0.42 per share to $0.40 per share should be recorded as a cost to induce the exercise of the warrants. As such, we recognized the difference of $21,218 between the fair value of the warrants before and after the modification as a cost in the accompanying statements of operations for the three and nine months ended December 31, 2014.
	In conjunction with the early exercise offer, we issued to the warrant holders who acted on such offer new, replacement warrants to purchase an additional 3,676,472 shares of our common stock. The terms and conditions of the replacement warrants are the same as the terms of the originally issued warrants, except that: (a) the initial exercise date is September 10, 2014 rather than June 28, 2013; (b) the replacement warrants have an exercise term of five years rather than nine months; (c) the exercise price of the replacement warrants is $0.45 per share (subject to anti-dilution and other adjustments as described below and a floor exercise price of $0.20 per share); and (d) the replacement warrants and the shares of common stock underlying such warrants are not registered under the Securities Act and are restricted securities. The new warrants are exercisable immediately upon issuance. These replacement warrants also provide for the adjustment of the exercise price and/or number of shares issuable upon exercise thereof in connection with stock dividends and splits, subsequent rights offerings, pro rata distributions to the Company’s common stockholders and subsequent equity sales by the Company at an effective price lower than the then-current exercise price of the replacement warrants. We determined that the fair value of these replacement warrants at their issue date of $940,549 was recorded as a cost to induce the exercise of the originally issued nine-month warrants in the accompanying statements of operations for the three and nine months ended December 31, 2014.
	In consideration of applicable guidance, the Company has determined that the warrants are not considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterized the fair value of these warrants of $940,549 as a derivative liability upon issuance (See Note 4).
	Warrants issued to employees
	On August 25, 2014, we entered into employment agreements with two new employees, pursuant to which, these employees became entitled to receive warrants to purchase an aggregate of 4,400,000 shares of the Company’s common stock. These warrants have an exercise price of $0.30, and a term of ten years from issue date. Vesting terms of these warrants are as follows: (i) warrants to purchase 800,000 shares of common stock vested immediately at their grant date, (ii) warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years, and (iii) warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement (See Note 9). During the nine months ended December 31, 2014, we expensed total stock-based compensation related to the vesting of these warrants of $355,742, and the remaining unamortized  cost of the outstanding warrants at December 31, 2014 was $753,498.
	The aggregate intrinsic value of all of the outstanding and exercisable warrants at December 31, 2014 was $104,000.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	9 Months Ended
	Dec. 31, 2014
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	8. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS
	Advance payment of related party lease
	On April 23, 2012, the Company entered into a lease agreement (the “Sutter Lease”) with Sutter Buttes LLC (“Sutter Buttes”), pursuant to which the Company has agreed to lease from Sutter Buttes approximately 1,000 acres of land in Sutter County, California. The Sutter Lease began on May 1, 2012 and the Company paid the aggregate amount of all rent payments thereunder, totaling $250,000, at the commencement of the lease. Sutter Buttes, the landlord under the Sutter Lease, is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains. The amount of all rent payments under the Sutter Lease of $250,000 was accounted for by the Company as an asset, Advance payment of related party lease, and was amortized over the term of the lease of 24 months. In April 2014, the Company recognized the remaining unamortized advance payment of $10,413 as rent expense related to the Sutter Lease. The Sutter Lease expired on May 1, 2014 and was not renewed and the Company is not renting or leasing the property after the expiration of the lease.
	Other related party lease obligations
	On April 23, 2012, the Company entered into a lease agreement (the “Carlson Lease”) with One World Ranches, LLC (“One World Ranches”), which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California. The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease.
	On August 18, 2012, the Company entered into a lease agreement (the “Sacramento Lease”) with Sacramento Valley Real Estate, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company has agreed to lease an apartment located at 33-800 Clark Avenue, Yuba City, California. The Company uses this apartment as an alternative to renting hotel rooms for management use since several of our managers are not resident in Yuba City. The month to month lease began on August 20, 2012 and the Company’s rent payment is $1,000 per month. On August 22, 2012, the Company paid $1,000 as a refundable security deposit under the Sacramento Lease.
	Aggregate payments under the above leases for the nine months ended December 31, 2014 and 2013 were $40,850 and $115,250, respectively.

DISTRIBUTION_AND_LICENSE_AGREE

DISTRIBUTION AND LICENSE AGREEMENTS	9 Months Ended
	Dec. 31, 2014
DISTRIBUTION AND LICENSE AGREEMENTS [Abstract]
DISTRIBUTION AND LICENSE AGREEMENTS	9. DISTRIBUTION AND LICENSE AGREEMENTS
	On August 25, 2014, we entered into a distribution agreement with Qualipride International (“Qualipride”), a stevia supplier located and organized in the People’s Republic of China, under which we became the exclusive worldwide distributor of Qualipride’s stevia products and acquired Qualipride’s customer list. Pursuant to the distribution agreement, Qualipride will supply products to the Company at its cost, plus up to 2% for handling costs and up to a 5% sales commission. We are obligated to hire and train sales personnel or appoint representatives to introduce, promote, market and sell Qualipride’s products worldwide. In addition, we must file a “generally recognized as safe” notice with the U.S. Food and Drug Administration for one or more of Qualipride’s stevia products prior to August 18, 2015.  The Company will account for such costs as such sales are made, or such other direct costs are incurred.  During the nine months ended December 31, 2014, neither any sales were made nor other direct cost were incurred pursuant to the terms of the distribution agreement.
	Concurrently, we also entered into a license agreement with Qualipride, Mr. Dong Yuejin and Mr. Guo Yuxiao, in which we obtained an exclusive license outside China to use Qualipride’s proprietary methods and designs for stevia extraction and purification facilities. Pursuant to the license agreement, we must obtain financing of at least $2.55 million prior to August 18, 2015 or the license granted to us will terminate, which funds we intend would be used to build a stevia extraction and purification facility in California. The license agreement also requires us to make payments to Qualipride of up to $700,000 upon securing required financing and achievement of certain other milestones, in addition to royalty payments of between $1.00 and $2.00 for each kilogram of certain specified stevia extracts produced at a California stevia production facility that is designed using the methods subject to the license grant. The Company will account for the costs of such license and obligation once such financing has been received.  During the nine months ended December 31, 2014, the Company did not receive any financing pursuant to the terms of the license agreement.
	Concurrently with such arrangements, we also entered into employment agreements with Mr. Dong and Mr. Guo.  Under the employment agreements, in addition to their base salaries, Mr. Dong and Mr. Guo are entitled to receive an aggregate of 2,400,000 restricted shares of our common stock (see Note 5) and warrants to purchase up to an aggregate of 4,400,000 shares of our common stock (see Note 7).  An aggregate of 400,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 800,000 shares of our common stock vested immediately upon issuance.  An aggregate of 1,000,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 2,000,000 shares of our common stock have vesting terms ranging from one to three years. An aggregate of 1,000,000 shares of our restricted common stock will be issued and warrants to purchase up to an aggregate of 1,600,000 shares of our common stock will vest once we achieve certain milestones, including reaching more than $5 million in annual revenue and the planned California stevia extraction and purification facility becoming operational and meeting certain technical performance specifications. The Company will account for the costs of the 1,000,000 shares of common stock and warrants to purchase up to an aggregate of 1,600,000 shares of common stock, at the time their issuance becomes probable.  During the period ended December 31, 2014, no such milestones were met.

BUSINESS_AND_BASIS_OF_OPERATIO1

BUSINESS AND BASIS OF OPERATIONS (Policies)	9 Months Ended
	Dec. 31, 2014
BUSINESS AND BASIS OF OPERATIONS [Abstract]
Basis of Presentation of Unaudited Condensed Financial Information	Basis of Presentation of Unaudited Condensed Financial Information
	The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”) .  Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete audited financial statements.  However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period .  The balance sheet information as of March 31, 2014 was derived from the audited financial statements as of and for the year ended March 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 30, 2014. These financial statements should be read in conjunction with that report.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of shares issued for services, the fair value of options and warrants, and assumptions used in the valuation of our outstanding derivative liabilities.
Accounts Receivable	Accounts Receivable
	The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding.
	The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At December 31, 2014, the allowance for doubtful accounts and returns and discounts was approximately $3,000.
Financial Assets and Liabilities Measured at Fair Value	Financial Assets and Liabilities Measured at Fair Value
	The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the condensed balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by the Financial Accounting Standards Board (“FASB”) defines the following levels directly related to the amount of objectivity associated with the inputs to fair valuation of these financial assets:
	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.
	Level 3	Unobservable inputs based on the Company’s assumptions.
	The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2014 and March 31, 2014:
	31-Dec-14
			Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability		$	-	$	1,488,535	$	-	$	1,488,535
	31-Mar-14
			Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability		$	-	$	1,438,814	$	-	$	1,438,814
	The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.
Derivative Financial Instruments	Derivative Financial Instruments
	The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2014 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Income Taxes	Income Taxes
	The Company follows the asset and liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Revenue Recognition	Revenue Recognition
	Revenue is recognized on the sale of a product when the risk of loss transfers to our customers and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and our credit acceptance procedures have been performed. The allowance for returns is regularly reviewed and adjusted by management based on historical trends of returned items. Amounts paid by customers for shipping and handling costs are included in sales.
Stock-Based Compensation	Stock-Based Compensation
	The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share
	The Company computes loss per share in accordance with FASB ASC 260, “Earnings Per Share” which requires presentation of both basic and diluted earnings or loss per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Diluted loss per share excludes all potential common shares if their effect is anti-dilutive.
	As of December 31, 2014 and 2013, the Company had potentially dilutive instruments outstanding whose shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive. Options to acquire 6,025,000 shares of common stock and warrants to acquire 12,127,129 shares of common stock have been excluded from the calculation at December 31, 2014, as the effect would have been anti-dilutive. Options to acquire 4,975,000 shares of common stock, warrants to acquire 7,721,129 shares of common stock, and 693,773 common shares potentially issuable under convertible note agreements have been excluded from the calculation at December 31, 2013, as the effect would have been anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In November 2014, the FASB issued Accounting Standards Update No. 2014-16 (ASU 2014-16), Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity.   The amendments in this ASU do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required.  The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract.  The ASU applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015.  Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2014-16 on the Company's results of operations or financial condition
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (“ASU 2014-15”),  Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.  An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.  ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2014-15 on the Company's results of operations or financial condition.
	On June 10, 2014, the FASB issued Accounting Standards Update No. 2014-10 (“ASU 2014-10”), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.  ASU 2014-10 eliminates the requirement that development stage entities present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 are no longer required for interim and annual reporting periods beginning after December 15, 2015, although early adoption is permitted. The Company adopted the provisions of ASU 2014-10 as of its Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers . ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principles-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on the Company’s ongoing financial reporting.
	In April 2014, the FASB issued Accounting Standards Update No. 2014-08 (“ASU 2014-08”), “Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ” ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations or that have a major effect on the Company's operations and financial results should be presented as discontinued operations. This new accounting guidance is effective for annual periods beginning after December 15, 2014. The Company is currently evaluating the impact of adopting ASU 2014-08 on the Company's results of operations or financial condition.
	Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Investments and Liabilities of Assets Measured at Fair Value on Recurring Basis	The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2014 and March 31, 2014:
	31-Dec-14
		Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability	$	-	$	1,488,535	$	-	$	1,488,535
	31-Mar-14
		Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability	$	-	$	1,438,814	$	-	$	1,438,814

DERIVATIVE_LIABILITY_Tables

STOCK OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2014
STOCK OPTIONS [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity for the nine months ended December 31, 2014 is presented below:
		Shares		Weighted Average Exercise Price
	Balance at March 31, 2014		5,150,000	$	0.26
	Granted		950,000		0.36
	Exercised		-50,000		0.10
	Cancelled		-25,000		0.47
	Balance outstanding at December 31, 2014		6,025,000	$	0.32
	Balance exercisable at December 31,2014		5,054,170	$	0.31
Options to Purchase Common Shares	At December 31, 2014, options to purchase common shares were outstanding as follows:
		Number of options		Weighted Average Exercise Price		Weighted Average Grant-date Stock Price
	Options Outstanding, December 31, 2014		1,300,000	$	0.10	$	1.00
			200,000	$	0.27	$	0.27
			100,000	$	0.31	$	0.31
			750,000	$	0.32	$	0.32
			50,000	$	0.33	$	0.33
			250,000	$	0.34	$	0.34
			500,000	$	0.35	$	0.35
			100,000	$	0.36	$	0.36
			150,000	$	0.38	$	0.38
			1,600,000	$	0.40	$	0.40
			225,000	$	0.42	$	0.42
			100,000	$	0.44	$	0.44
			100,000	$	0.47	$	0.47
			600,000	$	0.51	$	0.51
			6,025,000
	Options Exercisable, December 31, 2014		1,300,000	$	0.10	$	1.00
			166,666	$	0.27	$	0.27
			100,000	$	0.31	$	0.31
			750,000	$	0.32	$	0.32
			400,000	$	0.35	$	0.35
			33,336	$	0.36	$	0.36
			1,600,000	$	0.40	$	0.40
			79,168	$	0.42	$	0.42
			25,000	$	0.44	$	0.44
			600,000	$	0.51	$	0.51
			5,054,170

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2014
STOCK OPTIONS [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity for the nine months ended December 31, 2014 is presented below:
		Shares		Weighted Average Exercise Price
	Balance at March 31, 2014		5,150,000	$	0.26
	Granted		950,000		0.36
	Exercised		-50,000		0.10
	Cancelled		-25,000		0.47
	Balance outstanding at December 31, 2014		6,025,000	$	0.32
	Balance exercisable at December 31,2014		5,054,170	$	0.31
Options to Purchase Common Shares	At December 31, 2014, options to purchase common shares were outstanding as follows:
		Number of options		Weighted Average Exercise Price		Weighted Average Grant-date Stock Price
	Options Outstanding, December 31, 2014		1,300,000	$	0.10	$	1.00
			200,000	$	0.27	$	0.27
			100,000	$	0.31	$	0.31
			750,000	$	0.32	$	0.32
			50,000	$	0.33	$	0.33
			250,000	$	0.34	$	0.34
			500,000	$	0.35	$	0.35
			100,000	$	0.36	$	0.36
			150,000	$	0.38	$	0.38
			1,600,000	$	0.40	$	0.40
			225,000	$	0.42	$	0.42
			100,000	$	0.44	$	0.44
			100,000	$	0.47	$	0.47
			600,000	$	0.51	$	0.51
			6,025,000
	Options Exercisable, December 31, 2014		1,300,000	$	0.10	$	1.00
			166,666	$	0.27	$	0.27
			100,000	$	0.31	$	0.31
			750,000	$	0.32	$	0.32
			400,000	$	0.35	$	0.35
			33,336	$	0.36	$	0.36
			1,600,000	$	0.40	$	0.40
			79,168	$	0.42	$	0.42
			25,000	$	0.44	$	0.44
			600,000	$	0.51	$	0.51
			5,054,170

WARRANTS_Tables

WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2014
WARRANTS [Abstract]
Outstanding Warrants to Purchase Common Shares	At December 31, 2014, warrants to purchase common shares were outstanding as follows:
		Shares		Weighted Average Exercise Price
	Balance at March 31, 2014		7,727,129	$	0.41
	Granted		8,076,472		0.37
	Exercised		-3,676,472		0.40
	Cancelled		-	$	-
	Balance outstanding and exercisable at December 31, 2014		12,127,129	$	0.39

BUSINESS_AND_BASIS_OF_OPERATIO2

BUSINESS AND BASIS OF OPERATIONS (Narrative) (Details) (USD $)	9 Months Ended
	Dec. 31, 2014	Mar. 31, 2014
BUSINESS AND BASIS OF OPERATIONS [Abstract]
Accumulated deficit	$11,532,488	$8,326,861
Liquidity disclosure	We estimate that we will have sufficient funds to operate the business for the 9 months after December 31, 2014.

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares potentially issuable under convertible agreements excluded from calculation of earnings per share		693,773
Allowance for doubtful accounts receivable	3,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	12,127,129	7,721,129
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	6,025,000	4,975,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Investments and Liabilities of Assets Measured at Fair Value on Recurring Basis) (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Fair value of Derivative Liability	$1,488,535	$1,438,814
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Fair value of Derivative Liability	$1,488,535	$1,438,814

ACQUISITION_FROM_RELATED_PARTY1

ACQUISITION FROM RELATED PARTY (Narrative) (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	16-May-14
Business Acquisition [Line Items]
Accounts payable	$137,329	$79,915
Percipio Biosciences, Inc. [Member]
Business Acquisition [Line Items]
Purchase of assets from related party			50,000
Accounts payable	14,800
Senior scientist annual salary	$95,000
Percipio Biosciences, Inc. [Member] | Chief Executive Officer [Member]
Business Acquisition [Line Items]
Ownership percentage in acquired party held by an officer of reporting entity	20.00%

DERIVATIVE_LIABILITY_Narrative

DERIVATIVE LIABILITY (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Sep. 10, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability	$1,488,535		$1,488,535		$1,438,814
Change in fair value of derivative liability	-149,686	275,232	642,678	553,343
Cost to induce exercise of warrants		173,824	961,767	173,824
Replacement Warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability						940,549
Cost to induce exercise of warrants	940,549		940,549
Warrant Three [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of derivative liability			-269,368
Cost to induce exercise of warrants	$21,218		$21,218

DERIVATIVE_LIABILITY_Valuation

DERIVATIVE LIABILITY (Valuation Assumptions for Derivative Liabilities) (Details) (USD $)	0 Months Ended	3 Months Ended		0 Months Ended
	Sep. 10, 2014	Dec. 31, 2014	Mar. 31, 2014	Sep. 10, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Price		$0.37	$0.41
Expected volatility		81.84%	92.15%
Expected dividend yield	0.00%	0.00%	0.00%
Fair value of Derivative Liability		$1,488,535	$1,438,814
Date of Modification [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Price	0.42			$0.42
Expected volatility	84.45%
Fair value of Derivative Liability	961,767			$961,767
Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price		$0.45	$0.42
Risk-free interest rate		1.65%	1.73%
Expected life (in years)		4 years 9 months	4 years 3 months
Maximum [Member] | Date of Modification [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	0.45			$0.45
Risk-free interest rate				2.00%
Expected life (in years)				5 years
Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price		$0.34	$0.34
Risk-free interest rate		0.99%	0.07%
Expected life (in years)		2 years 9 months	6 months
Minimum [Member] | Date of Modification [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	0.4			$0.40
Risk-free interest rate				1.78%
Expected life (in years)				1 month 7 days

EQUITY_Narrative_Details

EQUITY (Narrative) (Details) (USD $)	9 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Nov. 30, 2014	Aug. 31, 2014	31-May-14	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining unvested shares, granted	950,000
Common stock issued for services, value	$324,100
Stock-based compensation, options vested (value)	177,271	868,497
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted during period	135,000
Common stock issued for services, shares			78,948
Common stock issued for services, value			30,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares	869,920		277,009	142,858	147,058	224,047
Common stock issued for services, value	870		100,000	50,000	50,000	94,100
Common Stock [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares issued during period	100,000
Unvested Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reclassification of unvested issued common stock to paid-in capital							149,714
Unvested Common Stock [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted during period	315,000
Employment Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amoritzation amount applied to share-based compensation expense	222,603
Employment Agreements [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares or warrants vested	450,000
Stock-based compensation, options vested (value)	135,000
Employment Agreements [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted during period	$315,000
Share-based compensation, nonvested shares (shares)	1,050,000		1,050,000
Employment Agreements [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares issued during period	1,500,000
Employment Agreements [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted	1 year
Employment Agreements [Member] | Maximum [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted	3 years

STOCK_OPTIONS_Narrative_Detail

STOCK OPTIONS (Narrative) (Details) (USD $)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining vesting period	2 years
Remaining unamortized cost of outstanding options	$224,880
Options outstanding, intrinsic value	441,000
Stock-based compensation, options vested (value)	177,271	868,497
Options exercisable, intrinsic value	419,500
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected discount rate of options granted	1.62%
Expiration period of options granted	10 years
Expected dividend rate of options granted	0.00%
Expected life of options granted	5 years
Options outstanding, intrinsic value	194,800
Options granted during period (shares)	700,000
Expected volatility rate of options granted	81.84%
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected discount rate of options granted	2.17%
Expected dividend rate of options granted	0.00%
Expected life of options granted	5 years
Options outstanding, intrinsic value	$59,750
Options granted during period (shares)	250,000
Expected volatility rate of options granted	81.84%
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted	0 months
Minimum [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted	5 years
Vesting period of options or warrants granted	0 months
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted	36 months
Maximum [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted	10 years
Vesting period of options or warrants granted	36 months

STOCK_OPTIONS_Summary_of_Stock

STOCK OPTIONS (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended
	Dec. 31, 2014
STOCK OPTIONS [Abstract]
Shares, beginning balance outstanding	5,150,000
Shares, Granted	950,000
Shares, Exercised	-50,000
Shares, Cancelled	-25,000
Shares, ending balance outstanding	6,025,000
Shares, Balance exercisable	5,054,170
Weighted Average Exercise Price, beginning balance outstanding	$0.26
Weighted Average Exercise Price, Granted	$0.36
Weighted Average Exercise Price, Exercised	$0.10
Weighted Average Exercise Price, Cancelled	$0.47
Weighted Average Exercise Price, ending balance outstanding	$0.32
Weighted Average Exercise Price, Balance exercisable	$0.31

STOCK_OPTIONS_Options_to_Purch

STOCK OPTIONS (Options to Purchase Common Shares) (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	6,025,000	5,150,000
Weighted Average Exercise Price, Options Outstanding	$0.32	$0.26
Number of Options Exercisable	5,054,170
Weighted Average Exercise Price, Options Exercisable	$0.31
Stock Options 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	1,300,000
Weighted Average Exercise Price, Options Outstanding	$0.10
Weighted Average Grant-Date Stock Price, Options Outstanding	$1
Number of Options Exercisable	1,300,000
Weighted Average Exercise Price, Options Exercisable	$0.10
Weighted Average Grant-Date Stock Price, Options Exercisable	$1
Stock Options 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	200,000
Weighted Average Exercise Price, Options Outstanding	$0.27
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.27
Number of Options Exercisable	166,666
Weighted Average Exercise Price, Options Exercisable	$0.27
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.27
Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	100,000
Weighted Average Exercise Price, Options Outstanding	$0.31
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.31
Number of Options Exercisable	100,000
Weighted Average Exercise Price, Options Exercisable	$0.31
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.31
Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	750,000
Weighted Average Exercise Price, Options Outstanding	$0.32
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.32
Number of Options Exercisable	750,000
Weighted Average Exercise Price, Options Exercisable	$0.32
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.32
Stock Options 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	50,000
Weighted Average Exercise Price, Options Outstanding	$0.33
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.33
Stock Options 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	250,000
Weighted Average Exercise Price, Options Outstanding	$0.34
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.34
Stock Options 7 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	500,000
Weighted Average Exercise Price, Options Outstanding	$0.35
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.35
Number of Options Exercisable	400,000
Weighted Average Exercise Price, Options Exercisable	$0.35
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.35
Stock Options 8 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	100,000
Weighted Average Exercise Price, Options Outstanding	$0.36
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.36
Number of Options Exercisable	33,336
Weighted Average Exercise Price, Options Exercisable	$0.36
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.36
Stock Options 9 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	150,000
Weighted Average Exercise Price, Options Outstanding	$0.38
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.38
Stock Options 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	1,600,000
Weighted Average Exercise Price, Options Outstanding	$0.40
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.40
Number of Options Exercisable	1,600,000
Weighted Average Exercise Price, Options Exercisable	$0.40
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.40
Stock Options 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	225,000
Weighted Average Exercise Price, Options Outstanding	$0.42
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.42
Number of Options Exercisable	79,168
Weighted Average Exercise Price, Options Exercisable	$0.42
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.42
Stock Options 12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	100,000
Weighted Average Exercise Price, Options Outstanding	$0.44
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.44
Number of Options Exercisable	25,000
Weighted Average Exercise Price, Options Exercisable	$0.44
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.44
Stock Options 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	100,000
Weighted Average Exercise Price, Options Outstanding	$0.47
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.47
Stock Options 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	600,000
Weighted Average Exercise Price, Options Outstanding	$0.51
Weighted Average Grant-Date Stock Price, Options Outstanding	$0.51
Number of Options Exercisable	600,000
Weighted Average Exercise Price, Options Exercisable	$0.51
Weighted Average Grant-Date Stock Price, Options Exercisable	$0.51

WARRANTS_Narrative_Details

WARRANTS (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended	0 Months Ended	3 Months Ended	1 Months Ended	4 Months Ended
	Jun. 25, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Sep. 10, 2014	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2014	Aug. 25, 2014
Class of Warrant or Right [Line Items]
Warrants issued (shares)	11,029,416		8,076,472
Exercise price of warrants			$0.39		$0.41		$0.39		$0.39
Aggregate intrinsic value of warrants outstanding			$104,000				$104,000		$104,000
Cost to induce exercise of warrants		173,824	961,767	173,824
Warrants exercised					3,676,472
Fair value of vested warrants granted to employees			355,742
Derivative liability			1,488,535		1,438,814		1,488,535		1,488,535
Warrants One [Member]
Class of Warrant or Right [Line Items]
Warrants issued (shares)	3,676,472
Exercise price of warrants	0.4
Warrant expiration period	5 years
Replacement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants issued (shares)						3,676,472
Exercise price of warrants						$0.45
Cost to induce exercise of warrants			940,549				940,549
Warrant expiration period						5 years
Floor exercise price of warrants						0.2
Derivative liability						940,549
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Warrants issued (shares)	3,676,472
Exercise price of warrants	0.42
Warrant expiration period	6 months
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Warrants issued (shares)	3,676,472
Number of shares called by early exercise of warrants						3,676,472
Exercise price of warrants	0.42					$0.40
Cost to induce exercise of warrants			21,218				21,218
Proceeds from issuance of common stock						1,470,589
Warrant expiration period	9 months
Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants					$0.42
Employment Agreement II [Member]
Class of Warrant or Right [Line Items]
Warrants issued (shares)								4,400,000
Exercise price of warrants										$0.30
Warrant vesting terms description									(i)B warrants to purchase 800,000 shares of common stock vested immediately at their grant date, (ii)B warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years, and (iii)B warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement
Warrant expiration period									10 years
Unamortized cost of outstanding warrants			753,498				753,498		753,498
Employment Agreement II [Member] | Warrant [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation			$355,742
Placement Agent Agreement [Member]
Class of Warrant or Right [Line Items]
Warrants issued (shares)	294,185
Exercise price of warrants	0.425
Warrant expiration period	5 years

WARRANTS_Warrants_to_Purchase_

WARRANTS (Warrants to Purchase Common Shares) (Details) (USD $)	0 Months Ended	9 Months Ended
	Jun. 25, 2013	Dec. 31, 2014
WARRANTS [Abstract]
Shares, Beginning Balance		7,727,129
Shares, Granted	11,029,416	8,076,472
Shares, Exercised		-3,676,472
Shares Outstanding, Balance		12,127,129
Shares, exercisable		12,127,129
Weighted Average Exercise Price, Balance		$0.41
Weighted Average Exercise Price, Granted		$0.37
Weighted Average Exercise Price, Exercised		$0.40
Weighted Average Exercise Price, Balance		$0.39
Weighted Average Exercise Price, Exercisable Balance		$0.39

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS (Narrative) (Details) (USD $)	9 Months Ended		0 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	1-May-12	Mar. 31, 2013	Aug. 22, 2012
Operating Leased Assets [Line Items]
Advance payment to related party	$10,413	$93,753
Operating leases, net rent expense	40,850	115,250
Sutter Buttes Llc [Member]
Operating Leased Assets [Line Items]
Advance payment to related party				-250,000
Advance payment on related party lease	10,413
Term of operating lease	24 months
Operating leases, net rent expense			250,000
Carlson Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month	2,300
Security deposit			1,500
Sacramento Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month	1,000
Security deposit					$1,000

DISTRIBUTION_AND_LICENSE_AGREE1

DISTRIBUTION AND LICENSE AGREEMENTS (Narrative) (Details) (USD $)	0 Months Ended	9 Months Ended	1 Months Ended	4 Months Ended
	Jun. 25, 2013	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2014
Distribution And License Agreements [Line Items]
Warrants issued (shares)	11,029,416	8,076,472
Annual revenue milestone		$5,000,000
Employment Agreement II [Member]
Distribution And License Agreements [Line Items]
Warrants issued (shares)			4,400,000
Warrant vesting terms description				(i)B warrants to purchase 800,000 shares of common stock vested immediately at their grant date, (ii)B warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years, and (iii)B warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement
Employment Agreement II [Member] | Share-based Compensation Award, Tranche One [Member]
Distribution And License Agreements [Line Items]
Warrant vesting terms description				vested immediately upon issuance
Employment Agreement II [Member] | Share-based Compensation Award, Tranche Three [Member]
Distribution And License Agreements [Line Items]
Warrant vesting terms description		will vest once we achieve certain milestones, including reaching more than $5 million in annual revenue and the planned California stevia extraction and purification facility becoming operational and meeting certain technical performance specifications
Common Stock [Member] | Employment Agreements [Member]
Distribution And License Agreements [Line Items]
Share-based compensation, shares issued during period		1,500,000
Warrant [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche One [Member]
Distribution And License Agreements [Line Items]
Number of warrants or shares vested			800,000
Warrant [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche Two [Member]
Distribution And License Agreements [Line Items]
Number of warrants or shares vested		2,000,000
Warrant [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche Three [Member]
Distribution And License Agreements [Line Items]
Warrants issued (shares)		1,600,000
Restricted Stock [Member] | Employment Agreement II [Member]
Distribution And License Agreements [Line Items]
Share-based compensation, shares issued during period		2,400,000
Restricted Stock [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche One [Member]
Distribution And License Agreements [Line Items]
Number of warrants or shares vested			400,000
Restricted Stock [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche Two [Member]
Distribution And License Agreements [Line Items]
Number of warrants or shares vested		1,000,000
Restricted Stock [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche Three [Member]
Distribution And License Agreements [Line Items]
Share-based compensation, shares issued during period		1,000,000
Maximum [Member] | Employment Agreements [Member] | Share-based Compensation Award, Tranche Two [Member]
Distribution And License Agreements [Line Items]
Vesting period of options or warrants granted		3 years
Maximum [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche Two [Member]
Distribution And License Agreements [Line Items]
Vesting period of options or warrants granted		3 years
Minimum [Member] | Employment Agreements [Member]
Distribution And License Agreements [Line Items]
Vesting period of options or warrants granted		1 year
Minimum [Member] | Employment Agreement II [Member] | Share-based Compensation Award, Tranche Two [Member]
Distribution And License Agreements [Line Items]
Vesting period of options or warrants granted		1 year
Licensing Agreements [Member] | Scenario, Forecast [Member]
Distribution And License Agreements [Line Items]
Minimum financing to be obtained pursuant to license agreement		2,550,000
Maximum required payments upon completion of milesetones		$700,000
Licensing Agreements [Member] | Maximum [Member] | Scenario, Forecast [Member]
Distribution And License Agreements [Line Items]
Royalty payments required pursuant to licensing agreement (dollars per kilogram)		2		2
Licensing Agreements [Member] | Minimum [Member] | Scenario, Forecast [Member]
Distribution And License Agreements [Line Items]
Royalty payments required pursuant to licensing agreement (dollars per kilogram)		1		1
Qualipride International [Member] | Maximum [Member]
Distribution And License Agreements [Line Items]
Handling charge, percent of product cost		2.00%
Sales commission charge as percent of product cost		5.00%